Halozyme Therapeutics (HALO) Net Margin (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Net Margin of 39.83% for Q1 2026, down 476.0% year-over-year from 10.59% in Q1 2025, and up 227.09% quarter-over-quarter from 31.34% in Q4 2025.
Halozyme Therapeutics (HALO) Net Margin (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Net Margin for 17 consecutive years, with 39.83% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin fell 476.0% year-over-year to 39.83%; the TTM figure through Mar 2026 stood at 23.13% (down 2163.0% YoY), while the FY2025 annual figure was 22.69%, down 2105.0% from the prior year.
- Net Margin advanced to 39.83% in Q1 2026 per HALO's latest filing, from 31.34% in the prior quarter.
- Across five years, Net Margin topped out at 51.25% in Q1 2022 and bottomed at 31.34% in Q4 2025.
- Historically, Net Margin has averaged 34.51% across 5 years, with a median of 39.22% in 2024.
- On a YoY basis, Net Margin climbed as much as 1992 bps in 2022 and fell as far as 15749 bps in 2022.
- Halozyme Therapeutics' Net Margin stood at 31.79% in 2022, then rose by 17 bps to 37.12% in 2023, then increased by 24 bps to 45.98% in 2024, then slumped by 168 bps to 31.34% in 2025, then soared by 227 bps to 39.83% in 2026.
- Business Quant data shows HALO's Net Margin at 39.83% in Q1 2026, 31.34% in Q4 2025, and 49.47% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 47.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.80% |
| Mar 31, 2026 | 39.83% |
| Dec 31, 2025 | -31.34% |
| Sep 30, 2025 | 49.47% |
| Jun 30, 2025 | 50.71% |
| Mar 31, 2025 | 44.59% |
| Dec 31, 2024 | 45.98% |
| Sep 30, 2024 | 47.23% |
| Jun 30, 2024 | 40.30% |
| Mar 31, 2024 | 39.22% |
| Dec 31, 2023 | 37.12% |
| Sep 30, 2023 | 37.88% |
| Jun 30, 2023 | 33.82% |
| Mar 31, 2023 | 24.43% |
| Dec 31, 2022 | 31.79% |
| Sep 30, 2022 | 29.49% |
| Jun 30, 2022 | 14.89% |
| Mar 31, 2022 | 51.25% |
| Dec 31, 2021 | 65.46% |
| Sep 30, 2021 | 186.99% |